JPS63502716A
(ja)
|
1986-03-07 |
1988-10-13 |
マサチューセッツ・インステチュート・オブ・テクノロジー |
糖タンパク安定性の強化方法
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US5605690A
(en)
|
1989-09-05 |
1997-02-25 |
Immunex Corporation |
Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
|
US5395760A
(en)
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
US5945397A
(en)
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
DE10399023I2
(de)
|
1989-09-12 |
2006-11-23 |
Ahp Mfg B V |
TFN-bindende Proteine
|
GB9022648D0
(en)
|
1990-10-18 |
1990-11-28 |
Charing Cross Sunley Research |
Polypeptide and its use
|
WO1993007863A1
(en)
|
1991-10-15 |
1993-04-29 |
Mullarkey Michael F |
Methods and compositions for treating allergic reactions
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
EP0620739A4
(en)
|
1992-09-15 |
1997-01-15 |
Immunex Corp |
Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
US5834266A
(en)
|
1993-02-12 |
1998-11-10 |
President & Fellows Of Harvard College |
Regulated apoptosis
|
US5869337A
(en)
|
1993-02-12 |
1999-02-09 |
President And Fellows Of Harvard College |
Regulated transcription of targeted genes and other biological events
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
WO1995026985A1
(en)
|
1994-04-05 |
1995-10-12 |
Board Of Regents, The University Of Texas System |
Modified receptors that continuously signal
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
US7094564B1
(en)
|
1995-03-15 |
2006-08-22 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor
|
EP0822984A4
(en)
|
1995-04-27 |
2000-05-03 |
Human Genome Sciences Inc |
TUMOR NECROSIS FACTOR RECEPTORS IN MEN
|
US7070783B1
(en)
|
1995-05-09 |
2006-07-04 |
The Mathilda And Terence Kennedy Institute Of Rheumatology |
Small molecular weight TNF receptor multimeric molecule
|
US5817789A
(en)
|
1995-06-06 |
1998-10-06 |
Transkaryotic Therapies, Inc. |
Chimeric proteins for use in transport of a selected substance into cells
|
US5721121A
(en)
|
1995-06-06 |
1998-02-24 |
Genentech, Inc. |
Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
|
US5705364A
(en)
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US5570401A
(en)
*
|
1995-09-22 |
1996-10-29 |
General Electric Company |
BWR containment configuration having partitioned wetwell airspace
|
AU5696198A
(en)
|
1996-12-06 |
1998-06-29 |
Amgen, Inc. |
Combination therapy using a tnf binding protein for treating tnf-mediated diseases
|
US6548644B1
(en)
|
1997-03-10 |
2003-04-15 |
Immunex Corporation |
Site protected protein modification
|
US6265535B1
(en)
|
1997-05-30 |
2001-07-24 |
The Trustees Of The University Of Pennsylvania |
Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
|
AU9376498A
(en)
|
1997-09-05 |
1999-03-22 |
University Of Washington |
Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
|
WO1999011662A1
(en)
|
1997-09-05 |
1999-03-11 |
Millennium Biotherapeutics, Inc. |
Novel molecules of the tnfr-ligand-related protein family and uses thereof
|
AU749332B2
(en)
|
1997-11-07 |
2002-06-27 |
Uab Research Foundation |
Method for the augmentation of gene expression
|
US6297367B1
(en)
|
1997-12-30 |
2001-10-02 |
Chiron Corporation |
Polynucleotide encoding TNFL1
|
WO1999041374A2
(en)
|
1998-02-17 |
1999-08-19 |
Incyte Pharmaceuticals, Inc. |
Human short-chain tnf-receptor family protein
|
JP2002505086A
(ja)
|
1998-02-25 |
2002-02-19 |
レキシジェン ファーマシューティカルズ コーポレイション |
抗体ベースの融合タンパク質の循環半減期の増強
|
DE69940808D1
(de)
|
1998-03-04 |
2009-06-10 |
Bristol Myers Squibb Co |
Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
PT1068241E
(pt)
|
1998-04-02 |
2007-11-19 |
Genentech Inc |
Variantes de anticorpos e respectivos fragmentos
|
EP1071769A1
(en)
*
|
1998-04-16 |
2001-01-31 |
Genentech, Inc. |
Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
|
US6451986B1
(en)
|
1998-06-22 |
2002-09-17 |
Immunex Corporation |
Site specific protein modification
|
SE9803710L
(sv)
|
1998-09-25 |
2000-03-26 |
A & Science Invest Ab |
Användning av vissa substanser för behandling av nervrotsskador
|
EP1123314B1
(en)
|
1998-10-20 |
2004-02-18 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Use of a cytokine-producing lactococcus strain to treat colitis
|
AU764479B2
(en)
|
1998-10-29 |
2003-08-21 |
Bristol-Myers Squibb Company |
Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
|
US7294481B1
(en)
|
1999-01-05 |
2007-11-13 |
Immunex Corporation |
Method for producing recombinant proteins
|
EP2364997A3
(en)
|
1999-01-15 |
2012-07-04 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6673908B1
(en)
|
1999-02-22 |
2004-01-06 |
Nuvelo, Inc. |
Tumor necrosis factor receptor 2
|
WO2000050436A1
(en)
|
1999-02-23 |
2000-08-31 |
Genaissance Pharmaceuticals, Inc. |
Receptor isogenes: polymorphisms in the tissue necrosis factor receptor
|
US20030148955A1
(en)
|
1999-04-19 |
2003-08-07 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
AU5636900A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
AU6836200A
(en)
|
1999-08-10 |
2001-03-05 |
Glaxo Group Limited |
Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
|
NZ529329A
(en)
|
1999-08-25 |
2005-06-24 |
Immunex Corp |
Compositions and methods for improved cell culture
|
GB9927681D0
(en)
|
1999-11-23 |
2000-01-19 |
Glaxo Group Ltd |
Protein
|
WO2001085782A2
(en)
|
2000-02-11 |
2001-11-15 |
Amgen Inc. |
Fusion receptor from tnf family
|
AU4314801A
(en)
|
2000-02-11 |
2001-08-20 |
Lexigen Pharm Corp |
Enhancing the circulating half-life of antibody-based fusion proteins
|
AU4541101A
(en)
|
2000-03-02 |
2001-09-12 |
Xencor Inc |
Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
ATE328605T1
(de)
|
2000-03-24 |
2006-06-15 |
Genentech Inc |
Verwendung von insulin zur behandlung von knorpelkrankheiten
|
US6800300B1
(en)
|
2000-03-31 |
2004-10-05 |
Vasogen Ireland Limited |
Method for treating autoimmune and alloimmune diseases
|
EP2322644A1
(en)
|
2000-06-28 |
2011-05-18 |
GlycoFi, Inc. |
Methods for producing modified glycoproteins
|
JP2004508043A
(ja)
|
2000-09-05 |
2004-03-18 |
アムジェン インコーポレイテッド |
Tnfレセプター様分子およびその使用
|
US6610750B1
(en)
|
2000-09-15 |
2003-08-26 |
Laboratoires Negma |
Treatment of osteoarthritis
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
US20020150582A1
(en)
|
2001-02-08 |
2002-10-17 |
Friedrichs Gregory S. |
Method of treating or inhibiting cellular injury or cell death
|
MXPA03007563A
(es)
|
2001-02-23 |
2003-12-11 |
Immunex Corp |
Recuperacion incrementada de proteinas activas.
|
US6972327B1
(en)
|
2001-05-08 |
2005-12-06 |
Immunex Corporation |
Regeneration of chromatography material
|
KR100453877B1
(ko)
*
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
ES2606840T3
(es)
|
2001-10-10 |
2017-03-28 |
Ratiopharm Gmbh |
Remodelación y glicoconjugación de factor estimulante de colonias de granulocitos (G-CSF)
|
RU2308455C2
(ru)
|
2001-11-07 |
2007-10-20 |
Ф.Хоффманн-Ля Рош Аг |
Аминопиримидины и пиридины
|
AU2002359816B2
(en)
|
2001-12-21 |
2006-07-13 |
Immunex Corporation |
Methods for purifying protein
|
EP1575480A4
(en)
|
2002-02-22 |
2008-08-06 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
|
AU2003219958B2
(en)
|
2002-02-27 |
2006-01-05 |
Immunex Corporation |
Polypeptide formulation
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
AU2003220529B2
(en)
|
2002-03-27 |
2006-09-07 |
Immunex Corporation |
Methods for increasing polypeptide production
|
US7067279B1
(en)
|
2002-08-23 |
2006-06-27 |
Immunex Corporation |
Cell culture performance with betaine
|
US6924124B1
(en)
|
2002-08-23 |
2005-08-02 |
Immunex Corporation |
Feeding strategies for cell culture
|
US6974681B1
(en)
|
2002-08-23 |
2005-12-13 |
Immunex Corporation |
Cell culture performance with vanadate
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
JP4351674B2
(ja)
|
2002-12-16 |
2009-10-28 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体とその使用法およびその使用
|
EP1613261A4
(en)
|
2003-04-09 |
2011-01-26 |
Novo Nordisk As |
INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
|
US7892563B2
(en)
|
2003-05-20 |
2011-02-22 |
Wyeth Holdings Corporation |
Methods for treatment of severe acute respiratory syndrome (SARS)
|
WO2004113387A2
(en)
|
2003-06-24 |
2004-12-29 |
Merck Patent Gmbh |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
SG145712A1
(en)
|
2003-08-01 |
2008-09-29 |
Amgen Inc |
Crystalline tumor necrosis factor receptor 2 polypeptides
|
WO2005014035A2
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk Health Care Ag |
Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
|
US7268116B2
(en)
|
2003-10-02 |
2007-09-11 |
Genhunter Corp. |
Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
|
KR20050082389A
(ko)
|
2004-02-18 |
2005-08-23 |
메덱스젠 주식회사 |
직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
|
US7507745B2
(en)
|
2004-02-20 |
2009-03-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
|
US20070048785A1
(en)
*
|
2004-06-09 |
2007-03-01 |
Lin Laura L |
Anti-IL-13 antibodies and complexes
|
JP4940136B2
(ja)
|
2004-06-28 |
2012-05-30 |
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド |
キメラタンパク質およびその使用
|
US7300773B2
(en)
|
2004-08-27 |
2007-11-27 |
Wyeth Research Ireland Limited |
Production of TNFR-Ig
|
JP2008528006A
(ja)
|
2005-01-28 |
2008-07-31 |
アポロ ライフ サイエンシズ リミテッド |
分子およびそのキメラ分子
|
WO2006083970A2
(en)
|
2005-01-31 |
2006-08-10 |
Ception Therapeutics, Inc. |
Tumor necrosis factor inhibitors
|
US8124732B2
(en)
|
2005-06-24 |
2012-02-28 |
Synageva Biopharma Corp. |
Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
|
US7956160B2
(en)
|
2005-07-22 |
2011-06-07 |
Amgen Inc. |
Concentrated protein lyophilates, methods, and uses
|
CN1954882A
(zh)
|
2005-10-14 |
2007-05-02 |
李海 |
长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途
|
US7626895B2
(en)
|
2005-12-01 |
2009-12-01 |
International Business Machines Corporation |
Removable media battery pack for powering a media accessor of an automated data-storage library
|
WO2008051306A1
(en)
|
2006-10-20 |
2008-05-02 |
Ercole Biotech, Inc. |
Soluble tnf receptors and their use in treatment of disease
|
US7504106B2
(en)
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
WO2008011633A2
(en)
|
2006-07-21 |
2008-01-24 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
WO2008025856A2
(en)
|
2006-09-01 |
2008-03-06 |
Novo Nordisk Health Care Ag |
Modified glycoproteins
|
TW200902708A
(en)
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
IL182956A0
(en)
|
2007-05-03 |
2008-01-20 |
Yeda Res & Dev |
Glycan modified soluble receptors and binding proteins and their use
|
EP2152751A1
(en)
|
2007-05-31 |
2010-02-17 |
Genmab A/S |
Fusion or linked proteins with extended half life
|
CN101778937A
(zh)
|
2007-06-04 |
2010-07-14 |
诺和诺德公司 |
使用n-乙酰葡糖胺转移酶的o-联糖基化
|
WO2009012600A1
(en)
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
CN108129573B
(zh)
|
2007-09-21 |
2021-10-08 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
US20100286067A1
(en)
|
2008-01-08 |
2010-11-11 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
PT3494986T
(pt)
|
2008-08-14 |
2020-07-14 |
Acceleron Pharma Inc |
Armadilhas para gdf
|
EP2440576A4
(en)
*
|
2009-06-08 |
2013-11-20 |
Acceleron Pharma Inc |
PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
|
KR20120028358A
(ko)
|
2009-06-12 |
2012-03-22 |
악셀레론 파마 인코포레이티드 |
절두된 ActRIIB-FC 융합 단백질
|
EP2507267B1
(en)
|
2009-12-02 |
2016-09-14 |
Acceleron Pharma, Inc. |
Compositions and methods for increasing serum half-life of fc fusion proteins
|
US8883982B2
(en)
*
|
2011-06-08 |
2014-11-11 |
Acceleron Pharma, Inc. |
Compositions and methods for increasing serum half-life
|